Chen Chen

CONTACT

Lead Sponsor

Central South University

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Cohort 1: Multi-omics study in early-stage synchronous multiple primary lung cancer
•1. Male or female patients:18-75 years old;
•2. ECOG score:0-1;
•3. Histopathologically confirmed TNM stage I-II NSCLC;
•4. Considered multiple or solitary primary lung cancer by clinical criteria (Martini-Melamed criteria and ACCP criteria);
•5. Good compliance, family members agree to cooperate to receive survival follow-up;
•6. Understand and voluntarily sign the informed consent.
•1. Male or female patients:18-75 years old;
•2. ECOG score:0-1;
•3. Histopathologically confirmed TNM stage I-II NSCLC;
•4. CT findings show solitary or multiple nodules with cystic airspaces.

•1. A history of previous or co-existing malignant tumors;
•2. Systemic anti-tumor therapies, including chemotherapy, radiotherapy, or targeted therapies (such as monoclonal antibodies, small-molecule tyrosine kinase inhibitors, among others), were administered prior to enrollment;
•3. Refusal to participate in the study.
•Cohort 2: Multi-omics study of lung cancer associated with cystic airspaces
•1. A history of previous or co-existing malignant tumors;
•2. Systemic anti-tumor therapies, including chemotherapy, radiotherapy, or targeted therapies (such as monoclonal antibodies, small-molecule tyrosine kinase inhibitors, among others), were administered prior to enrollment;
•3. Refusal to participate in the study.